Monday, May 23, 2022

Apeiron plans COVID-19 trial of inhaled ACE2 formulation

Apeiron Biologics is preparing to study an inhaled formulation of its ACE2 receptor decoy APN01. The clinical trial will test whether switching from intravenous to inhaled delivery can expand the patient population for the COVID-19 candidate.

Vienna-based Apeiron began studying APN01 in COVID-19 in the belief the soluble form of ACE2 may stop the coronavirus from entering human cells. The idea is that the molecule could serve as a decoy receptor, reducing ACE2-mediated entry into cells, while also acting on a peptide system involved in blood pressure, inflammation and the prevention of organ damage. 

A phase 2 clinical trial of APN01 in hospitalized COVID-19 patients missed its primary endpoint earlier this year, but Apeiron has continued to forge ahead, securing a spot on the National Institutes of Health-backed ACTIV-4d trial and hatching plans to run its own study of an inhaled formulation.

“Delivery of our drug candidate directly to the respiratory tract could block viral entry into the lung cells and control inflammation. Importantly, APN01 may also be suitable against infections with variants of SARS-CoV-2 as already preclinically shown,” Romana Gugenberger, Apeiron’s head of R&D, said in a statement.

Apeiron plans to start the inhalation study in the third quarter.  The change of delivery routes reflects a belief that inhalation could enable Aperion “to target all infected or at-risk patients earlier in the course of the disease.” Apeiron said ACE2-based therapeutics have shown “high efficacy” in animal models. The company is planning a financing round to fund development. 

Work on the intravenous formulation of APN01 is continuing with external support. The Vanderbilt Institute for Clinical and Translational Research has included the drug in ACTIV-4d, a 1,600-subject study that is assessing multiple therapies that may restore the renin angiotensin aldosterone system in COVID-19 patients. 

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...